Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
复制标题
DOI：
10.1097/qad.0b013e328342328b
复制
发表时间：
2011-01-28
期刊：
影响因子：
--
通讯作者：
Fauci AS
中科院分区：
文献类型：
--
作者：
Ho J;Moir S;Wang W;Posada JG;Gu W;Rehman MT;Dewar R;Kovacs C;Sneller MC;Chun TW;Follmann DA;Fauci AS
评估接受抗逆转录病毒治疗的HIV感染病毒血症个体和未感染个体对低剂量AS 03佐剂和标准剂量无佐剂2009年大流行H1N1甲型流感疫苗的体液免疫反应。一项三臂研究。两个诊所：一个在美国马里兰州贝塞斯达的国立卫生研究院;另一个在加拿大安大略多伦多的枫叶医疗诊所。艾滋病毒感染者和未感染艾滋病毒的成年人。单次肌肉注射15µg剂量的单价灭活2009年甲型H1N1流感大流行疫苗（不含佐剂）或3.75µg剂量的相同毒株（含佐剂AS 03）。免疫原性，通过血凝抑制（HAI）抗体滴度和疫苗特异性记忆B细胞应答测定。共招募了74名参与者。21名艾滋病毒感染者接种了低剂量的2009年大流行性H1N1甲型流感疫苗。29名HIV感染者和24名HIV未感染者接受了标准剂量的无佐剂疫苗。在研究的三组中，接种后9周的抗体应答无显著差异。然而，与接受标准剂量无佐剂疫苗的HIV感染组和未感染组相比，接受低剂量佐剂疫苗的HIV感染组对疫苗的IgG记忆B细胞应答显著更高。在对年龄、性别、CD 4 + T细胞计数和基线HAI滴度进行回归校正后，结论保持不变。这些数据表明，佐剂可用于扩大覆盖范围，通过剂量节省和改善免疫功能低下的个人的体液免疫反应。
To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1 influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals. A three-arm study. Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada. HIV-infected and HIV-uninfected adults. Single intramuscular 15µg dose of the monovalent inactivated 2009 pandemic H1N1 influenza A vaccine without adjuvant or 3.75µg dose of the same strain with adjuvant AS03. Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses. A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1 influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4+ T-cell count, and baseline HAI titer. These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.